Text Size

MMF Influence on HCV Viral Evolution After Liver Transplantation

This study has been completed.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT00170131
First received: September 13, 2005
Last updated: May 20, 2011
Last verified: May 2011
History of Changes
  Purpose

Samples from a large clinical trial comparing three immunosuppression regimens, two of which contained MMF, are used to identify the HCV viral quasispecies behaviour after liver transplantation


Condition Phase
HCV Infection
Liver Transplantation
 Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: The Influence MMF on 5UTR HCV Quasispecies Variation: A Potential Factor in the Natural History of Post-OLT x HCV Infection

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Enrollment: 17
Study Start Date: September 2002
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Sampling Method:   Non-Probability Sample
Study Population

All patients enrolled into - An Open Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety Among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection

Criteria

All patients enrolled into - An Open Randomized, Prospective Multicenter Study to Compare the Efficacy and Safety Among Three Immunosuppressant Treatment Regimens in Patients Receiving a Liver Transplant for End-Stage Liver Disease Caused by Chronic Hepatitis C Infection

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00170131

Locations
United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
Sponsors and Collaborators
Mayo Clinic
Hoffmann-La Roche
Investigators
Principal Investigator: Hugo E. Vargas, M.D. Mayo Clinic
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00170131     History of Changes
Other Study ID Numbers: 1801-02, CEL358
Study First Received: September 13, 2005
Last Updated: May 20, 2011
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on June 17, 2013